Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

2.6%

1 terminated/withdrawn out of 38 trials

Success Rate

97.2%

+10.7% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

0%

0 of 35 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
34(97.1%)
Phase 4
1(2.9%)
35Total
N/A(34)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials
NCT06035276Not ApplicableCompleted

Biosensor and Environmental Sensor Development Within the REMEDIA Project

Role: lead

NCT06317909Not ApplicableRecruiting

Development of a Novel Non-invasive Inflammometry Following Allergen Challenge in Patients With Mild Allergic Asthma

Role: lead

NCT02522026Completed

Follow-up-study of COPD Patients and Healthy Controls for Evaluation of Predictive Non-coding RNA Biomarkers

Role: lead

NCT05346718Not ApplicableCompleted

Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis

Role: lead

NCT04914273Not ApplicableCompleted

Use of Exhaled Particles to Assess Lung Pharmacokinetics

Role: lead

NCT05245175Not ApplicableCompleted

Impact of Carrier Solutions for House Dust Mite Allergen on Allergic Reactions

Role: lead

NCT05019209Not ApplicableCompleted

Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients

Role: lead

NCT04895124Completed

Second Follow-up Study of COPD Patients and Healthy Controls for Evaluation of Predictive Non-coding RNA Biomarkers

Role: lead

NCT01088633Not ApplicableCompleted

Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Role: lead

NCT05249062Not ApplicableCompleted

SHAPES: Supporting Multimorbid Older People

Role: collaborator

NCT04231214Phase 4Completed

Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects

Role: lead

NCT04771585Not ApplicableCompleted

Quantification of Exhaled Particles to Identify Airborne Transmission Risks of COVID-19

Role: lead

NCT03665701Not ApplicableCompleted

Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites

Role: lead

NCT03772405Not ApplicableCompleted

Effect of the Nasal Gel "Nascum®-Plus" on Allergic Symptoms

Role: lead

NCT03524066Not ApplicableCompleted

Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)

Role: lead

NCT03450031Not ApplicableCompleted

Evaluation of Nasal Inflammatory Biomarkers

Role: lead

NCT03575312Not ApplicableCompleted

Pharmacokinetics of Enrofloxacin in Plasma and Urine

Role: lead

NCT03044327Not ApplicableCompleted

Development of Novel Non-invasive Inflammometry Following Lipopolysaccharide, Endotoxin (LPS) Challenge in Healthy Volunteers

Role: lead

NCT03315611Not ApplicableCompleted

Study to Assess the Effect of "Eucerin AtopiControl" on Dermal Symptoms in Patients With Atopic Dermatitis

Role: lead

NCT03076086Not ApplicableCompleted

Investigation of Secreted Phosphoproteins and PiP3 (Phosphoinositolphospat 3) in Sputum

Role: lead